Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sapacitabine - Cyclacel Pharmaceuticals

Drug Profile

Sapacitabine - Cyclacel Pharmaceuticals

Alternative Names: CS-682; CYC-682

Latest Information Update: 25 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company; Hokkaido University; Kanazawa University
  • Developer Cyclacel Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Arabinonucleosides; Small molecules
  • Mechanism of Action Cell cycle inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Breast cancer; Solid tumours
  • No development reported Ovarian cancer
  • Discontinued Cutaneous T-cell lymphoma

Most Recent Events

  • 14 May 2019 Cyclacel Pharmaceuticals plans a phase I trial for Acute myeloid leukaemia and Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater, Refractory metastatic disease) (PO), in 2019
  • 29 Mar 2019 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
  • 27 Mar 2019 Cyclacel Pharma plans to determine the regulatory pathway and submissibility of sapacitabine for Acute myeloid leukaemia (In the elderly) in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top